Your browser doesn't support javascript.
loading
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara; Iamsawat, Supinya; Andrejeva, Gabriela; Luevano, Libia A; Wolf, Melissa; Baliga, Uday; Krieg, Carsten; Beeson, Craig C; Mehrotra, Meenal; Hill, Elizabeth G; Rathmell, Jeffery C; Yu, Xue-Zhong; Kraft, Andrew S; Mehrotra, Shikhar.
Afiliação
  • Chatterjee S; Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.
  • Chakraborty P; Department of Surgery, Medical University of South Carolina, Charleston, South Carolina.
  • Daenthanasanmak A; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
  • Iamsawat S; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
  • Andrejeva G; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Luevano LA; University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.
  • Wolf M; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Baliga U; Department of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Krieg C; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
  • Beeson CC; Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina.
  • Mehrotra M; Department of Pathology & Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Hill EG; Department of Public Health, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Rathmell JC; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Yu XZ; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina.
  • Kraft AS; University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.
  • Mehrotra S; Department of Surgery, Medical University of South Carolina, Charleston, South Carolina. mehrotr@musc.edu.
Clin Cancer Res ; 25(3): 1036-1049, 2019 02 01.
Article em En | MEDLINE | ID: mdl-30327305
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Bifenilo / Linfócitos T / Imunoterapia Adotiva / Ensaios Antitumorais Modelo de Xenoenxerto / Proteínas Proto-Oncogênicas c-pim-1 / Tiazolidinas / Receptor de Morte Celular Programada 1 / Neoplasias Experimentais Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Bifenilo / Linfócitos T / Imunoterapia Adotiva / Ensaios Antitumorais Modelo de Xenoenxerto / Proteínas Proto-Oncogênicas c-pim-1 / Tiazolidinas / Receptor de Morte Celular Programada 1 / Neoplasias Experimentais Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article